MétaCan
Menu
← Back to cohort
Record W4407284953 · doi:10.1093/jcag/gwae059.085

A85 PATTERN OF SEMAGLUTIDE PRESCRIPTION IN A REAL-WORLD PATIENT COHORT

2025· article· en· W4407284953 on OpenAlexaffabout
Armin Farahvash, M Lee, Rahul Jain, Liisa Jaakkimainen

Bibliographic record

VenueJournal of the Canadian Association of Gastroenterology · 2025
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsSemaglutideMedical prescriptionCohortMedicineInternal medicinePharmacologyEndocrinologyDiabetes mellitusType 2 diabetes

Abstract

fetched live from OpenAlex

Abstract Background The weight-loss effects of semaglutide has been studies in many randomized controlled trials. However, real-world data on its use is limited, particularly in the Canadian healthcare setting. Aims This study aims to explore the pattern of semaglutide prescription and associated outcomes in an academic family medicine practice in Canada. Methods We conducted a retrospective study of patients at the Sunnybrook Hospital family health team in Toronto, Ontario. Patients aged ≥18 years who were prescribed semaglutide between January 2018 and April 2024 were included. Baseline demographics and follow-up safety and efficacy measures were collected up to 16 months after semaglutide initiation. Results Of the 9930 rostered patients, 368 (3.71%) were prescribed semaglutide during the study period. The average age of patients who were prescribed semaglutide was 57.7±14.1 years and 63.3% were female. The average BMI was 36.6±7.84 kg/m2 and 189 patients (51.4%) had diabetes. The indication for semaglutide prescription was weight-loss for 206 patients (56.0%), diabetes for 118 patients (32.1%), and both weight-loss and diabetes for 39 patients (10.6%). We observed that since 2018, there has been a growing number of family physicians prescribing semaglutide compared to endocrinologists. In 2023 and 2024, over 80% of all semaglutide prescribers for our patients were family physicians, and endocrinologists were in the minority. Despite being prescribed semaglutide, 20 patients (5.4%) did not initiate the medication and 66 (17.9%) discontinued it within 16 months. Reasons for discontinuation included gastrointestinal adverse effects (26/66, 39.4%), difficulty in access (30/66, 54.5%), and perceived lack of response (6/66, 9.1%). Baseline and follow up weights were recorded for 211 patients (57.3%). Mean weight-loss was 7.36%. Mean weight-loss by 16 months was significantly greater in patients without diabetes (8.83% vs. 6.18%, p=0.003) and in females (8.30% vs. 5.90%, p=0.009), although there were more females without diabetes compared to males. The mean HbA1c at follow-up was 6.5±1.1%, which represents a significant reduction of 10.7% from baseline (p <0.001). Conclusions Our analysis of a real-world cohort of patients who used semaglutide demonstrated its wight-loss effects, particularly in those without diabetes. Understanding the demographics of patients using semaglutide and its potential effects will help inform future prescription practices. Funding Agencies None

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.423
Threshold uncertainty score0.841

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.003
Science and technology studies0.0010.001
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.006
GPT teacher head0.230
Teacher spread0.224 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueJournal of the Canadian Association of Gastroenterology→Same topicDiabetes Treatment and Management→French-language works237,207→